AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01582347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subutex®/Suboxone®
Description: Participants randomized to the Subutex®/Suboxone® treatment arm take the dosage of either drug on which they were previously stabilised during the Run-In, Transfer, and Transition Periods.~Participants randomized to the RBP-6300 treatment arm take the dosage of either drug on which they were previously stabilised during the Run-In and Transition Periods.~Sublingual Subutex® tablets containing 8 mg buprenorphine and and sublingual Suboxone® tablets containing 8 mg buprenorphine and 2 mg naloxone.
Study NCT01582347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for RBP-6300
Description: Participants randomized to the Subutex®/Suboxone® treatment arm take Placebo for RBP-6300 during the Transfer and Transition Periods.~Participants randomized to the RBP-6300 treatment arm take Placebo for RBP-6300 during the Transition Period.
Study NCT01582347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for RBP-6300
Description: Participants randomized to the Subutex®/Suboxone® treatment arm take Placebo for RBP-6300 during the Transfer and Transition Periods.~Participants randomized to the RBP-6300 treatment arm take Placebo for RBP-6300 during the Transition Period.
Study NCT01582347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Subutex®/Suboxone®
Description: Participants randomized to the RBP-6300 treatment arm take Placebo for Subutex®/Suboxone® during the Transfer Period.
Study NCT02453048 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPZE1
Description: Intranasal live, attenuated vaccine
Study NCT02453048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Diluent
Study NCT04358523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC18
Description: ASC18：ravidasvir and sofosbuvir fixed Dose Combination 200 mg/400 mg
Study NCT04358523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ravidasvir and sofosbuvir
Description: RDV 200 mg and SOF 400 mg
Study NCT02576496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinostamustine
Study NCT03282864 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Bedroom air filtered by an air filtration device to remove airborne pollutants
Description: The air in the bedroom of study subjects in the active comparator arm was processed by an air filtration device which pulled air through a pre-filter, a high efficiency particular air (HEPA) filter and an active carbon filter continuously. The air in the bedroom of subjects in the placebo arm was processed by a placebo air filtration device that looked identical to the real air filtration device but did not possess the HEPA filter and the active carbon filter. Each subject was assigned to the active comparator arm and the placebo arm in a randomized order with a two-week washout period scheduled in-between. The subjects, their guardians and the study staff that assessed the health indicators of the subjects were blinded to this order till the end of the study.
Study NCT03282864 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bedroom air filtered by an air filtration device to remove airborne pollutants
Description: The air in the bedroom of study subjects in the active comparator arm was processed by an air filtration device which pulled air through a pre-filter, a high efficiency particular air (HEPA) filter and an active carbon filter continuously. The air in the bedroom of subjects in the placebo arm was processed by a placebo air filtration device that looked identical to the real air filtration device but did not possess the HEPA filter and the active carbon filter. Each subject was assigned to the active comparator arm and the placebo arm in a randomized order with a two-week washout period scheduled in-between. The subjects, their guardians and the study staff that assessed the health indicators of the subjects were blinded to this order till the end of the study.
Study NCT04226443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam intravenous injection
Description: The midazolam was prepared as 5 mg midazolam in 20 mL syringe of 5% dextrose water solution (0.25 mg/mL) in both arms. Both groups of patients received an intravenous bolus dose of midazolam was administered before the start of the surgery. In Group 1, continuous infusion of intravenous midazolam was started and in Group 2, intravenous bolus doses of midazolam were administered. The doses were adjusted depending on pain level and sedation level using appropriate scales for monitoring during the surgical time period. The drip rate was adjusted according to pain intensity. The infusion of drugs was discontinued at the end of the procedure.
Study NCT04226443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil intravenous bolus dose
Description: A remifentanil infusion was prepared as follows; 0.5 mg remifentanil was added into 100 mL of 0.9% saline at a concentration of 5 μg/mL. The preparation of remifentanil solution and installation of the device was done by an anesthesiologist who was blinded for the study groups. The dose and number of patients that required remifentanil were recorded. The infusion of drugs was discontinued at the end of the procedure. A rescue medication of intravenous remifentanil bolus dose was used as 1 to 3 mL (5 μg or 15 μg) every 5 minutes if necessary for pain scores greater than 3. This infusion was prepared prior to the use during the study and was discontinued at the end of the procedure.
Study NCT00089388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilengitide
Description: Given IV
Study NCT04582617 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa Extract
Description: 2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine
Study NCT04582617 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa Extract Placebo
Description: Cocoa extract placebo
Study NCT02794974 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical plexus block
Description: ultrasound-guided application of 20ml ropivacaine 0.75%
Study NCT02794974 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: facial nerve block
Description: ultrasound-guided application of 5ml prilocaine 1%
Study NCT02794974 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: perivascular block
Description: ultrasound-guided application of 5ml prilocaine 1%
Study NCT01029340 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Factor VIII (BAY81-8973)
Description: Single dose of BAY81-8973 crossed over to single dose of Kogenate FS
Study NCT01029340 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Description: Single dose of Kogenate FS crossed over to Single dose of BAY81-8973
Study NCT01029340 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Factor VIII (BAY81-8973)
Description: Participants received IV injections of BAY81-8973 at 20-50 IU/kg 2-3 times per week with BAY81-8973 measured by Chromogenic Substrate Assay Potency Per European Pharmacopeia (CS/EP) for 6 months and by Chromogenic Substrate Assay/Adjusted to Label Potency (CS/ADJ) for 6 months, sequence according to randomization.
Study NCT01029340 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Factor VIII (BAY81-8973)
Description: Participants received a loading dose of approximately 50 IU/kg of BAY 81-8973 before the first surgical incision followed by further treatment with BAY 81-8973 according to surgical requirements for up to 3 weeks
Study NCT01131195 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab, Paclitaxel
Description: Bevacizumab (10 mg/kg) i.v. is given every two weeks. Paclitaxel (90 mg/m2) i.v. is given on days 1, 8, and 15 of a 4 week cycle.
Study NCT01131195 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab, Cyclophosphamide, Capecitabine
Description: Bevacizumab (10 mg/kg) i.v. is given every two weeks. Cyclophosphamide (50 mg) and capecitabine (3x 500 mg) p.o. are given daily
Study NCT01411969 — intervention group
Intervention type: DRUG
Intervention: External Nasal Dilator Strip; 0.05% oxymetazoline chloride
Description: External Nasal Dilator Strip placed above the upper lateral cartilage; 20 minutes after decongestion with 0.05% oxymetazoline chloride applied as an aerosol spray (two times); after decongestion with ENDS.
Study NCT02668718 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Adjuvant radiotherapy
Description: The radiation therapy will be given in 37 fractions of 1.8 Gy per day, five days per week. The total dose of radiation will be 66.6 Gy.
Study NCT00529971 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR group
Description: 8-week MBSR group, 3 hours per week plus one all day retreat
Study NCT00529971 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Treatment as usual, which could include medications or psychotherapy
Study NCT00958139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Permethrin
Description: Permethrin 0.5% treatment of clothing one time
Study NCT00958139 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: water sprayed on clothing one time
Study NCT02215603 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breaking prolonged sitting with physical activity
Study NCT04741724 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEDS
Description: An non-invasive intervention. During the intervention, the electrode was placed on the skin stimulated muscle.
Study NCT02437162 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive Placebo subcutaneous (SC) injection at Weeks 0, 4, and 16 in Group 1 and at Week 24 in Group 2 and Group 3.
Study NCT02437162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo subcutaneous (SC) injection at Weeks 0, 4, and 16 in Group 1 and at Week 24 in Group 2 and Group 3.
Study NCT02437162 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ustekinumab 45 mg
Description: Participants will receive Ustekinumab 45 mg SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing, with the last administration of study agent at Week 100 in Group 1. Participants will start with ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 100 in Group 2.
Study NCT02437162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Description: Participants will receive Ustekinumab 45 mg SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing, with the last administration of study agent at Week 100 in Group 1. Participants will start with ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 100 in Group 2.
Study NCT02437162 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ustekinumab 90 mg
Description: Participants will receive Ustekinumab 90 mg SC injection at Weeks 24 and 28 followed by q12w dosing, with the last administration of study agent at Week 100 in Group 1. Participants will start with ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 100 in Group 3.
Study NCT02437162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Description: Participants will receive Ustekinumab 90 mg SC injection at Weeks 24 and 28 followed by q12w dosing, with the last administration of study agent at Week 100 in Group 1. Participants will start with ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 100 in Group 3.
Study NCT02437162 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Golimumab 50 mg
Description: Participants who meet EE criteria (less than \[\<\] 10 percent \[%\] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52 in Groups 1, 2 and 3.
Study NCT02437162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg
Description: Participants who meet EE criteria (less than \[\<\] 10 percent \[%\] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52 in Groups 1, 2 and 3.
Study NCT03856255 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micro-Tech Endoscopic Gauge
Description: Use of Micro-Tech Endoscopic Gauge to measure any polyp detected during a screening or surveillance colonoscopy.
Study NCT03535623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: remote ischemic preconditioning (RIPC)
Description: RIPC consists of 4 cycles of 5-min ischemia using pneumatic cuff pressure of 200 mmHg and 5-min reperfusion.
Study NCT03535623 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham-RIPC
Description: Sham-RIPC consists of 4 cycles of 5-min ischemia using pneumatic cuff pressure of \< 10 mmHg and 5-min reperfusion.
Study NCT03333070 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotic - Lactobacillus reuteri
Description: The treated arm will receive 5 drops per day for 48 weeks
Study NCT03333070 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo - with no active ingredient
Description: The control arm will receive 5 drops per day for 48 weeks
Study NCT03064139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MCG
Description: Community-based in person group training n mindful walking over 11 sessions in 6-months+ Activity monitor with feedback on activity levels
Study NCT03064139 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SCG
Description: Community-based in person group education in management of knee osteoarthritis (importance of physical activity, weight management, etc.) over 11 sessions in 6 months + Activity monitor with feedback on activity levels
Study NCT04232735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tool and training
Description: The Source tool aims to assist health care providers with giving evidence based information about treatment outcomes by providing visualizations of personalized predictions of treatment outcomes for different treatments of oesophageal and gastric cancer. These predictions result from recently designed and updated prediction models on the survival, toxicity, complications and health related quality of life of oesophageal and gastric cancer patients.~The training aims to teach participants to inform patients about outcomes of treatment. The training is placed in the context of shared decision making (SDM), following the 4-step model by Stiggelbout et al., 2015.8 The training is provided in small groups (3-6 participants) by an experienced trainer and supported by professional actors. The training aims to address knowledge, attitude and skills.
Study NCT02574637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brazikumab IV Infusion
Description: Brazikumab IV infusion as per protocol specified dosing schedule.
Study NCT02574637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Brazikumab IV Infusion
Description: Brazikumab IV infusion as per protocol specified dosing schedule.
Study NCT02574637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brazikumab SC Injection
Description: Brazikumab IV infusion as per protocol specified dosing schedule.
Study NCT02574637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Brazikumab SC Injection
Description: Brazikumab IV infusion as per protocol specified dosing schedule.
Study NCT02574637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching Brazikumab IV infusion as per protocol specified dosing schedule.
Study NCT02574637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching Brazikumab IV infusion as per protocol specified dosing schedule.
Study NCT04311086 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal Denervation (Symplicity Spyral™)
Description: Device: Symplicity Spyral™ multi-electrode renal denervation system. After a renal angiography according to standard procedures, subjects are treated with the renal denervation procedure.
Study NCT00682266 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intensity controlled interval training (AIT)
Description: 4 x 4 min intervals at 90% of maximal heart rate, each interval separated by 3 min at 70%, twice a week for 3 months
Study NCT00682266 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidisciplinary approach (MTG)
Description: exercise, dietary and psychological advice, twice a month for 12 months
Study NCT03591445 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexible Bronchoscopy
Description: Flexible Bronchoscopy
Study NCT01175902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dorzolamide/timolol
Description: dorzolamide/timolol fixed combination eyedrop, 2 times a day
Study NCT01175902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost
Description: compare with dorzolamide/timolol fixed combination eyedrop one time a day
Study NCT03098836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARN-509
Description: 240 mg orally daily
Study NCT03098836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: 1000 mg orally daily
Study NCT03098836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg orally twice daily (for total daily dose 10 mg)
Study NCT01420146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zr89-trastuzumab
Description: trastuzumab labelled with zirconium 89 for PET/CT
Study NCT04189679 — intervention group
Intervention type: OTHER
Intervention: Immune signature in serum associated to the metabolic signature
Description: Immune signature in serum associated to the metabolic signature
Study NCT04189679 — intervention group
Intervention type: GENETIC
Intervention: Meta-genomic signature of intestinal flora
Description: Meta-genomic signature of intestinal flora
Study NCT02648126 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pure Red Cell Aplasia diagnostic confirmation
Description: Patients who meet the appropriate criteria in the selection period will be subject to Pure Red Cell Aplasia diagnostic confirmation by collecting 20 mL of blood in dialysis units.~The samples will be processed, aliquoted and transported to Bio-Manguinhos, where depart periodically (according to the volume of samples) to the reference laboratory Sce Immunologie et d'Hématologie biologiques Hôpital Saint Antoine, where the dosage of antibody will be held anti epoetin alfa
Study NCT01764074 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Sleep Intervention
Description: Participants will meet with a therapist for three sessions to try to improve sleep problems (hypersomnia or insomnia, depending on the problems the participant has).
Study NCT01887977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI examination
Description: The vocal and nasal tracts from the lips and nostrils to the beginning of the trachea are imaged with Siemens Avanto 1.5T MRI machine using carefully optimized, externally triggered imaging sequences that are synchronized with the rest of the experimental setting. A sound sample, given by the test subject, is recorded simultaneously to obtain a coupled data set: the speech sound and the precise anatomy which produces it.
Study NCT03067909 — intervention group
Intervention type: OTHER
Intervention: CIED surgery
Study NCT01463098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2006 1.0 mg
Description: E2006 1.0 mg capsule.
Study NCT01463098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2006 2.5 mg
Description: E2006 2.5 mg capsule.
Study NCT01463098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2006 5.0 mg
Description: E2006 5.0 mg (2 capsules of 2.5 mg each).
Study NCT01463098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2006 10.0 mg
Description: E2006 10.0 mg capsule.
Study NCT01463098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2006 25.0 mg
Description: E2006 25.0 mg (2 capsules of 10 mg each and 2 capsules of 2.5 mg each).
Study NCT01463098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2006 50.0 mg
Description: E2006 50.0 mg capsule.
Study NCT01463098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2006 100 mg
Description: E2006 100 mg (2 capsules of 50 mg each).
Study NCT01463098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2006 200 mg
Description: E2006 200 mg (4 capsules of 50 mg each).
Study NCT01463098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Description: Zolpidem 10 mg immediate release tablet.
Study NCT01463098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2006 Matched Placebo or Zolpidem Matched Placebo
Description: E2006-matched placebo capsules or zolpidem-matched placebo tablets.
Study NCT01463098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2006 Matched Placebo
Description: E2006-matched placebo capsule.